Abstract
© 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of
Original language | English |
---|---|
Pages (from-to) | 222-225 |
Number of pages | 4 |
Journal | Endocrine |
Volume | 52 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2016 |